XL-protein and GENERIUM sign broad therapeutic license and collaboration agreement to develop PASylated therapeutics for the Russian Federation
Freising, Germany & Moscow, Russia, June 25, 2013
XL-protein…
XL-protein and Wacker Biotech produce a PASylated antibody fragment (Fab) with prolonged plasma half-life at more than four grams per liter culture in an E. coli expression system
High Yield with ESETEC® and PASylation®: Wacker Biotech and…
Wacker Biotech and XL-protein Sign Long-Term Cooperation Agreement to Produce PASylated Biopharmaceuticals
Munich / Freising / Jena, October 30, 2012
Wacker Biotech…